It is worth mentioning that large-scale genomic studies of human cancer demonstrated that AKT1-E17K is the most common AKT mutation and improves the efficacy of AKT inhibitor therapy in solid tumors [87,96]. The gene discussed is AKT1; the disease is cancer.